Request Info


Ask for our annual reports or more information
Email Us

Email Alerts

Sign up for email alerts
Email Alerts
Investor Relations

News Releases

RSS RSS Feeds
News Release Search
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998
DateTitle  
11/26/2007Meridian Bioscience Receives FDA Clearance for Two New Rapid Tests for the Detection of Influenza and Respiratory Syncytial Virus
CINCINNATI--(BUSINESS WIRE)--Nov. 26, 2007--Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market two new upper respiratory tests: TRU FLU(R) and TRU RSV(R). These tests are based upon a new rapid test technology that features improved safety and space savings. TRU FLU(R) detects both influenza A and influenza B while TRU RSV(R) detects for respiratory syncytial virus. These companion tests are... 
 Printer Friendly Version
11/14/2007Meridian Bioscience Reports Record Fiscal 2007 Operating Results, Increases Regular Cash Dividend Rate, and Reaffirms Guidance
CINCINNATI--(BUSINESS WIRE)--Nov. 14, 2007--Meridian Bioscience, Inc. GENERAL HIGHLIGHTS Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: -- reported record fourth quarter and full-year fiscal 2007 net sales of $32.4 million and $123.0 million, respectively, increases of 13% over the same periods of the prior fiscal year; -- reported record fourth quarter and full-year fiscal 2007 operating income of $8.6 mi... 
 Printer Friendly Version
9/20/2007Meridian Bioscience to Present at the UBS Global Life Science Conference
CINCINNATI--(BUSINESS WIRE)--Sept. 20, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company has been invited to present at the UBS Global Life Science Conference at the Grand Hyatt New York in New York City. Bill Motto, Chairman and CEO and Jack Kraeutler, President and COO, are scheduled to present on Wednesday, September, 26, 2007 at 2:00 p.m. ET. A question and answer session will follow and some of the information provided during the ses... 
 Printer Friendly Version
9/19/2007Meridian Bioscience to Present at the Sidoti & Company, LLC Sixth Annual West Coast Emerging Growth International Investor Forum
CINCINNATI--(BUSINESS WIRE)--Sept. 19, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that the Company has been invited to present at the Sidoti & Company, LLC Sixth Annual West Coast Emerging Growth International Investor Forum at the Ritz-Carlton Hotel in San Francisco. Bill Motto, Chairman and CEO and Jack Kraeutler, President and COO, are scheduled to present on Monday, September, 24, 2007 at 9:40 a.m. PDT. A question and answer session will follow... 
 Printer Friendly Version
8/28/2007Meridian Bioscience, Inc. Announces the Commencement of Phase I/II Clinical Trials of Parvovirus B19 Vaccine
CINCINNATI--(BUSINESS WIRE)--Aug. 28, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced the commencement of a Phase I/II Clinical Trial for a Parvovirus B19 Vaccine manufactured by its wholly owned subsidiary, Meridian Life Science, located in Memphis, Tennessee. The Investigational New Drug (IND) Application for the Parvovirus B19 Vaccine was a collaborative effort between Meridian Life Science and two branches of the National Institutes of Health (NIH),... 
 Printer Friendly Version
8/14/2007Meridian Bioscience Provides Sales and Earnings Guidance for Fiscal 2008 and Reaffirms Fiscal 2007 Guidance
CINCINNATI--(BUSINESS WIRE)--Aug. 14, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today provided the financial community with guidance regarding the Company's fiscal 2008 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2008, management expects net sales to be in the range of $140 to $142 million and per share diluted earnings to be between $0.72 and $0.75. The per share estimat... 
 Printer Friendly Version
8/7/2007Meridian Bioscience Awarded NIH Contract for Production of Experimental Vaccines
CINCINNATI--(BUSINESS WIRE)--Aug. 7, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its wholly owned subsidiary, Meridian Life Science, Inc. (MLS) was awarded a five year contract (base year plus 4 option years) having a value of up to $12.2 million by the National Institutes of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). Meridian will manufacture up to 10 clinical experimental vaccines per year at its bioph... 
 Printer Friendly Version
7/19/2007Meridian Bioscience Reports Record Operating Results, Declares Regular Cash Dividend, Reaffirms Higher Fiscal 2007 Guidance, and Comments on Fiscal 2008 Outlook
CINCINNATI--(BUSINESS WIRE)--July 19, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: -- reported record third quarter and nine-month sales of $29,763,000 and $90,577,000, respectively, an increase of 12% and 14% over the same periods of the prior fiscal year; -- reported record third quarter and nine-month operating income of $9,473,000 and $26,350,000, respectively, an increase of 37% and 31% over the same period... 
 Printer Friendly Version
6/5/2007Meridian Bioscience Increases Earnings Per Share and Net Sales Guidance for Fiscal 2007
CINCINNATI--(BUSINESS WIRE)--June 5, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today increased its previous guidance for fiscal 2007 earnings from a range of $0.55 to $0.58 per share (as adjusted for the May 11, 2007 three-for-two stock split) to a new range of $0.57 to $0.60 per share. The per share estimates assume an increase in average shares outstanding from approximately 40.2 million at fiscal 2006 year end to 40.5 million at fiscal 2007 year end. Net sales... 
 Printer Friendly Version
5/3/2007Meridian Bioscience to Present at the Robert W. Baird 2007 Growth Stock Conference
CINCINNATI, May 03, 2007 (BUSINESS WIRE) -- Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that the Company has been invited to present at the Robert W. Baird 2007 Growth Stock Conference on Thursday, May 10, 2007 at 12:35 p.m. CDT at the Four Seasons Hotel in Chicago. Bill Motto, Chairman and Chief Executive Officer and Jack Kraeutler, President and Chief Operating Officer, are scheduled to present. A question and answer session will follow the Company's presentation. The informa... 
 Printer Friendly Version
4/19/2007Meridian Bioscience Reports Record Second Quarter and Six Months Operating Results, Splits Stock 3 for 2, and Increases Dividend
General Highlights CINCINNATI--(BUSINESS WIRE)--April 19, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: reported record second quarter and six months net sales of $32,094,000 and $60,814,000, respectively, an increase of 14% over the same periods of the prior fiscal year; reported record second quarter and six months net earnings of $5,881,000 and $11,445,000, respectively, an increase of 25% and 32% over ... 
 Printer Friendly Version
2/20/2007Meridian Bioscience Receives FDA Clearance for New E. coli Test
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to market ImmunoCard STAT!® EHEC, a revolutionary new test for the diagnosis of E. coli infection. The new product detects all Shiga-toxin producing E. coli and is the first rapid (20 minute) E. coli diagnostic that differentiates between Toxin 1 & Toxin 2. With the recent national E. coli outbreaks (spinach in September 2006 and lettuce i... 
 Printer Friendly Version
1/30/2007Meridian Bioscience Announces Final Redemption of its 5% Convertible Subordinated Debentures
CINCINNATI--(BUSINESS WIRE)--Jan. 30, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that it has called for redemption on March 1, 2007, all of its outstanding 5% Convertible Subordinated Debentures due September 1, 2013, at a 1% call premium plus accrued interest. At January 29, 2007, there were approximately $1.5 million of principal amount of such debentures outstanding. On or prior to the close of business on February 27, 2007, holders of the ... 
 Printer Friendly Version
1/18/2007Meridian Bioscience Reports Record First Quarter Sales and Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2007 Guidance
GENERAL HIGHLIGHTS CINCINNATI--(BUSINESS WIRE)--Jan. 18, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today: -- reported record first quarter net sales of $28,720,000, a 15% increase over the same period of the prior fiscal year; -- reported record quarterly net earnings of $5,564,000, a 40% increase over the same period of the prior fiscal year; -- reported record first quarter diluted per share earnings of $0.21,... 
 Printer Friendly Version
1/4/2007Meridian Bioscience Completes Production of Clinical Respiratory Syncytial Virus (RSV) for Human Clinical Trials
CINCINNATI--(BUSINESS WIRE)--Jan. 4, 2007--Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced that its wholly owned subsidiary, Meridian Life Science, Inc. (MLS), formerly Viral Antigens, Inc., completed manufacturing of a clinical infectious inoculum of respiratory syncytial virus (RSV) in its biopharmaceutical facility located in Memphis, TN. The RSV clinical material will be used by a contract biopharmaceutical client to conduct human challenge studies in ord... 
 Printer Friendly Version